Inoviv

Inoviv’s approach to protein analysis speeds up results, making them 7 times more cost-effective than competitors. Their core technology uses AI algorithms to design peptides for reagents that are then sent to external labs for analysis together with customer-provided samples. External labs then use mass-spectrometry analysis protocols to generate raw data that is fed back to Inoviv's servers for analysis and graph generation of the results. Inoviv has been able to achieve high margins of 80-85% by charging for results while not having to do measurements internally.
Founders / Management Michael Dove, Ernestas Sirka
Sectors Protein analysis, Drug development, Clinical trials
Located in London, UK
Co-Investors Hoxton Ventures, Foresight Group, Ada Ventures, Entrepreneur First
Follow On

LinkedIn

Sign up to receive our weekly newsletter and learn about investing in technologies that are changing the world.